文献速递精神分裂症与精神病性障碍

精神病作为毒蕈碱信号障碍:精神病理学与药理学

Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology.
PubMed 文献 · Lancet Psychiatry · 2024-05-22

本文综述中枢毒蕈碱系统及临床前、行为、尸检和神经影像学证据,探讨毒蕈碱信号异常在精神病病理生理中的作用,并回顾毒蕈碱药物治疗精神病的临床证据。

要点

  • 多巴胺受体拮抗是现有抗精神病药的共同机制,但毒蕈碱受体激动剂在部分临床试验中亦有效。
  • 临床前、行为、尸检和神经影像学证据提示毒蕈碱系统参与精神病病理生理。
  • 毒蕈碱信号改变可能促发并维持精神病性症状,需未来研究阐明其与症状的关系。

核心结论

  • 毒蕈碱信号异常可能参与精神病病理生理,毒蕈碱受体激动剂在部分临床试验中显示抗精神病疗效。

研究设计与样本

  • 综述,讨论中枢毒蕈碱系统并检视临床前、行为、尸检和神经影像学证据及毒蕈碱药物治疗的临床证据。

主要发现

  • 多巴胺受体拮抗是所有获批抗精神病药的关键成分,多巴胺功能异常是精神病性症状病理生理模型的核心。
  • 部分临床试验提示通过毒蕈碱受体激动起效的药物也可有效治疗精神病,可能提示毒蕈碱异常参与精神病病理生理。
  • 临床前、行为、尸检和神经影像学证据支持毒蕈碱系统参与精神病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dopaminergic receptor antagonism is a crucial component of all licensed treatments for psychosis, and dopamine dysfunction has been central to pathophysiological models of psychotic symptoms. Some clinical trials, however, indicate that drugs that act through muscarinic receptor agonism can also be effective in treating psychosis, potentially implicating muscarinic abnormalities in the pathophysiology of psychosis. Here, we discuss understanding of the central muscarinic system, and we examine preclinical, behavioural, post-mortem, and neuroimaging evidence for its involvement in psychosis. We then consider how altered muscarinic signalling could contribute to the genesis and maintenance of psychotic symptoms, and we review the clinical evidence for muscarinic agents as treatments. Finally, we discuss future research that could clarify the relationship between the muscarinic system and psychotic symptoms.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. McCutcheon RA, Weber LAE, Nour MM, et al. Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology. Lancet Psychiatry. 2024. PMID: 38795721. doi:10.1016/S2215-0366(24)00100-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。